A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients

Launched by ASCENTAGE PHARMA GROUP INC. · Jun 26, 2019

Keywords

ClinConnect Summary

This clinical trial is investigating a new treatment approach for patients with a type of lung cancer called EGFR positive non-small cell lung cancer (NSCLC) who have not responded to standard therapies. The study is looking at the combination of two drugs: APG-1252 and osimertinib (a type of targeted therapy known as TKI). Researchers want to learn about how safe and effective this combination is for patients who have either already tried osimertinib without success or have never been treated with it.

To be eligible for this trial, participants should be adults aged 18 or older with advanced NSCLC that has been confirmed by a doctor, and they must have a specific genetic mutation called an EGFR mutation. Patients who have had at least one previous treatment, including an EGFR TKI, are welcome to join. Throughout the study, participants will receive the new treatment and will be monitored closely for any side effects and how well the cancer responds. The trial is actively recruiting participants, and anyone considering joining should be ready to provide a recent tumor sample and follow specific study procedures.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• Only applicable to the dose-finding stage:
• • Patients with NSCLC with disease progression after first-line EGFR TKI and platinum-based chemotherapy.
• Only applicable to dose-expansion stage:
• • Cohort 1: Patients with NSCLC with disease progression after third-generation EGFR TKI and platinum-based chemotherapy.
• • Cohort 2: Patients with NSCLC with disease progression after first- or second-generation EGFR TKI and platinum-based chemotherapy.
• • Cohort 3: Patients with advanced EGFR-mutated NSCLC not previously treated with TKI.
• Applicable to any phase:
• • 1. Histologically or cytologically confirmed incurable advanced or metastatic non-small cell lung cancer.
• • 2. At least 1 measurable lesion (RECIST 1.1).
• • 3. Confirmed EGFR mutation positive before start use prior EGFR TKI(s) .
• • 4. Willing to biopsy or to supply achieved tumor sample which biopsy after the most recent treatment.
• • 5. Male or female patients age ≥18 years.
• • 6. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1.
• • 7. Estimated OS ≥3 months.
• • 8. Adequate hematologic and bone marrow functions.
• • 9. Adequate renal and liver function.
• • 10. Brain metastases with clinically controlled neurologic symptoms.
• • 11. Had recovered from all toxicities related to prior anticancer therapies to grade ≤ 2, except for patients with grade 2 nausea/vomiting and/or grade 2 diarrhea despite optimal supportive therapy who will not be allowed to participate in the study.
• • 12. Willingness to use contraception by a method that is deemed effective by the investigator by both males and female patients of child bearing potential (postmenopausal women must have been amenorrhea for at least 12 months to be considered of non-childbearing potential) and their partners throughout the treatment period and for at least three months following the last dose of study drug.
• • 13. Ability to understand and willingness to sign a written informed consent form (the consent form must be signed by the patient prior to any study-specific procedures).
• • 14. Willingness and ability to comply with study procedures and follow-up examination.
• Exclusion Criteria:
• • 1. Received chemotherapy, radiation therapy, surgery, immunotherapy, hormonal therapy, targeted therapy, biologic therapy (hormones for hypothyroidism or estrogen replacement therapy (ERT), anti-estrogen analogs, agonists required to suppress serum testosterone levels are permitted); or any investigational therapy; , or has had tumor embolization or tumor lysis syndrome (TLS) within 28 days prior to the first dose of study drug.
• • 2. Received TKIs targeted therapy (except third generation EGFR TKIs) within 14 days prior to the first dose of study drug.
• • 3. A history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis requiring steroid therapy, or any evidence of clinically active interstitial lung disease.
• • 4. Any of the following cardiac criteria: screening period resting period QTC \> 470 milliseconds (clinical electrocardiograph report value; if a single time\> 470 milliseconds, take the average of 3 inspections); rhythm of resting electrocardiogram (ECG), any clinically important abnormality of conduction or morphology (e.g., complete left bundle branch block, Grade 3 heart block, Grade 2 heart block); family history of congenital long QT prolongation syndrome or long QT syndrome.
• • 5. Evidence of any serious or uncontrolled systemic disease; various chronic active infections such as hepatitis B (HBV-DNA ≥ 104 copy number/ml or 2000 IU/ml), hepatitis C and HIV; uncontrollable Hypertensive patients (requires 2 or more drugs to control blood pressure); unstable angina; angina pectoris within 3 months prior to study; congestive heart failure (NYHA class II or higher); myocardial infarction (NSTEMI or STEMI) history in 6 months before study enrollment; severe arrhythmia requiring medical attention; severe liver, kidney, gastrointestinal or metabolic diseases.
• • 6. Patients who are unable to stop taking drugs or herbal medicine that are strong inhibitors or inducers of CYP3A within 1 week before the first study drug administration and during the treatment. However, patients who discontinue use of these compounds at least 1 week prior to receiving this regimen are eligible.
• • 7. Hemorrhagic constitution/disease, such as a history of non-chemotherapy-induced thrombocytopenic hemorrhage or a history of ineffective platelet transfusion within 1 year prior to the first dose of study drug; Severe gastrointestinal bleeding occurred within 3 months prior to the first dose of study drug; Active immune thrombocytopenic purpura (ITP), active autoimmune hemolytic anemia (AIHA), etc.
• • 8. Use a therapeutic dose of anticoagulant or antiplatelet agent before the first use of APG-1252 or within 7 days of central catheter placement (if platelet count is stable (≧50×109/L), Subjects who previously received aspirin to prevent thrombosis therapy can reuse low-dose aspirin (i.e., up to 100 mg QD) after 3 weeks of study drug treatment; Decisions regarding anticoagulants and antiplatelet therapy will be determined by the investigator and the sponsor; Allow low-dose anticoagulant drugs to maintain central venous catheters open.
• • 9. Received a biologic (G-CSF, GM-CSF or erythropoietin) within 28 days prior to the first dose of study drug.
• • 10. According to the investigator's judgment, patients who did not fully recover after surgery. Patients who underwent major surgery within 28 days prior to the first study drug and who underwent minor surgery within 7 days prior to the start of the study.
• • 11. Other malignancies have been diagnosed within 5 years prior to the first use of the study drug; except effectively treated skin basal cell carcinoma, cutaneous squamous cell carcinoma, and/or effectively resected orthotopic cervical cancer and/or breast cancer.
• • 12. Female patients during pregnancy or lactation.
• • 13. Previous allergies or intolerance to treatment with osimertinib.
• • 14. A diagnosis of febrile neutropenia within one week prior to the first use of the study drug.
• • 15. Prior treatment with Bcl-2/Bcl-xL inhibitors.
• • 16. Any other condition or circumstance of that would, in the opinion of the investigator, make the patient unsuitable for participation in the study.